本文選題：lncRNAs + 腎透明細(xì)胞癌�。� 參考：《華東師范大學(xué)》2017年碩士論文

【摘要】：癌癥是一種形成原因特別復(fù)雜的慢性疾病,遺傳方面的因素、生活環(huán)境的好壞都可能會(huì)決定個(gè)體是否會(huì)患上癌癥。近期的一些研究報(bào)道表明,lncRNAs(long non-coding RNAs,長(zhǎng)鏈非編碼核糖核酸)在腫瘤發(fā)生過程和癌癥患者的預(yù)后中扮演重要的角色,由此激發(fā)了人們對(duì)lncRNAs在癌癥預(yù)后中具有潛在臨床相關(guān)的作用及機(jī)理進(jìn)行了一系列研究。腎細(xì)胞癌(簡(jiǎn)稱腎癌)是人體泌尿系統(tǒng)器官中惡性度較高的一種腫瘤,也是人體所有腫瘤中最常見的腫瘤之一,起源于腎實(shí)質(zhì)泌尿小管上皮系統(tǒng)的惡性腫瘤,又被稱為腎腺癌,占所有腎惡性腫瘤的85%～95%。通常病理學(xué)家將腎細(xì)胞癌分為4種類型:腎透明細(xì)胞癌、乳頭狀腎細(xì)胞癌、嫌色細(xì)胞性腎細(xì)胞癌以及Bellini集合管癌。其中,絕大多數(shù)為腎透明細(xì)胞癌,占腎癌的70%～80%,其癌細(xì)胞常排列成片狀、條索狀、腺泡狀或管狀。然而,lncRNAs標(biāo)記作為一種生物標(biāo)記在腎透明細(xì)胞癌(ccRCC,clear cell renal cell carcinoma)患者的預(yù)后中起什么樣作用,尚未被深入研究和討論。因此,我們?cè)噲D去尋找與腎透明細(xì)胞癌患者預(yù)后顯著相關(guān)的一些lncRNAs。首先,我們?cè)诎┌Y和腫瘤基因圖譜計(jì)劃公共數(shù)據(jù)庫(kù)(TCGA)中,提取了帶有臨床信息數(shù)據(jù)的440個(gè)腎透明細(xì)胞癌患者數(shù)據(jù),并對(duì)這組數(shù)據(jù)中l(wèi)ncRNAs的表達(dá)值進(jìn)行分析。在對(duì)總的數(shù)據(jù)集分組后的訓(xùn)練集以及測(cè)試集中,我們發(fā)現(xiàn)并驗(yàn)證了五個(gè)與腎透明細(xì)胞癌患者預(yù)后顯著相關(guān) lncRNAs(AC069513.4、AC003092.1、CTC-205M6.2、RP11-507K2:3、U91328.21)。基于這五個(gè)預(yù)后相關(guān)的lncRNAs,樣本中的腎透明細(xì)胞癌患者可被分為高風(fēng)險(xiǎn)和低風(fēng)險(xiǎn)組兩種組別。其中,存在于不同組別的患者的存活率明顯不同。多變量Cox回歸分析表明,這五個(gè)預(yù)后相關(guān)的lncRNAs具有相對(duì)于其他臨床因素而言的獨(dú)立的預(yù)后價(jià)值。進(jìn)一步的功能富集分析還顯示出這五個(gè)預(yù)后相關(guān)的lncRNAs在腫瘤形成過程中所發(fā)揮的潛在作用。所有的生存分析的結(jié)果都表明,這五個(gè)預(yù)后相關(guān)的lncRNAs對(duì)于腎透明細(xì)胞癌患者預(yù)后來說,很有可能作為一個(gè)獨(dú)立而又重要的生存指標(biāo)。
[Abstract]:Cancer is a very complicated chronic disease, genetic factors, living conditions can determine whether an individual will have cancer. Recent studies have shown that long non-coding RNASs play an important role in tumorigenesis and prognosis in cancer patients. This has stimulated a series of studies on the potential clinicopathological roles and mechanisms of lncRNAs in cancer prognosis. Renal cell carcinoma (RCC) is a kind of tumor with high malignancy in the organs of human urinary system. It is also one of the most common tumors in all human tumors. It originates from the malignant tumor of renal parenchymal urothelial system and is also called renal adenocarcinoma. It accounts for 85% of all malignant renal tumors. Usually, renal cell carcinoma is classified into four types by pathologists: clear cell carcinoma of kidney, papillary renal cell carcinoma, chromophobic renal cell carcinoma and Bellini collecting tube carcinoma. Most of them are clear cell carcinoma of the kidney, accounting for 70% of renal carcinoma. Its cancer cells are usually arranged in sheet, stripe, acinar or tubular form. However, the role of lncRNAs as a biomarker in the prognosis of patients with clear renal cell carcinoma (CCCC) clear cell renal cell carcinoma) has not been further studied and discussed. Therefore, we try to look for some lncRNAs that are significantly associated with the prognosis of renal clear cell carcinoma. Firstly, we extracted 440 data of renal clear cell carcinoma with clinical data from cancer and tumor gene map program public database (TCGA), and analyzed the expression of lncRNAs in these data. In the training set and test set after grouping the total data sets, we found and verified five significant correlations between the prognosis of clear cell renal carcinoma patients and the prognosis of five patients with clear cell carcinoma of kidney AC069513.4% AC003092.1 CTC-205M6.2n RP11-507K2: 3 U91328.21. Based on the five prognostic factors lncRNAs. the patients with renal clear cell carcinoma in the sample were divided into two groups: high risk group and low risk group. The survival rates of patients in different groups were significantly different. Multivariate Cox regression analysis showed that these five prognostic lncRNAs had independent prognostic value compared with other clinical factors. Further functional enrichment analysis also revealed the potential role of these five prognostic lncRNAs in tumor formation. All the results of survival analysis show that these five prognostic lncRNAs are likely to be an independent and important prognostic marker for the prognosis of renal clear cell carcinoma (RCC) patients.
【學(xué)位授予單位】：華東師范大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R737.11

【參考文獻(xiàn)】

相關(guān)期刊論文 前1條

1 Zheng Yang;Lu Yu;Zhe Wang;;PCA3 and TMPRSS2-ERG gene fusions as diagnostic biomarkers for prostate cancer[J];Chinese Journal of Cancer Research;2016年01期

，

本文編號(hào)：1968420